Scope
Reference
C371747
Description
Vaccine mimic materials-comprising messenger RNA (mRNA) and lipid nanoparticles (LNPs)-from Helix-Biotech.
Contract 1. Helix Biotech Biosimilar mRNA Vaccines
Supplier
Contract value
- £150,000 excluding VAT
- £180,000 including VAT
Above the relevant threshold
Earliest date the contract will be signed
1 October 2025
Contract dates (estimated)
- 1 October 2025 to 30 September 2027
- 2 years
Main procurement category
Goods
CPV classifications
- 33651600 - Vaccines
Contract locations
- UK - United Kingdom
Participation
Particular suitability
Small and medium-sized enterprises (SME)
Other information
Description of risks to contract performance
A valid and current Cyber Essentials Certificate is required.
Conflicts assessment prepared/revised
Yes
Procedure
Procedure type
Direct award
Direct award justification
Single supplier - technical reasons
Helix-Biotech Inc. is the only supplier capable of delivering the required vaccine mimic materials (mRNA encapsulated in LNPs). Their proprietary methodology and formulation capability are not available from other suppliers, nor covered under any current public procurement frameworks.
Supplier
Helix Biotech, Inc.
- Public Procurement Organisation Number: PCMD-6995-GBGZ
1460 Breda Drive
Knoxville
37918
United States
Email: info@helix-biotech.com
Small or medium-sized enterprise (SME): Yes
Voluntary, community or social enterprise (VCSE): No
Contract 1. Helix Biotech Biosimilar mRNA Vaccines
Contracting authority
UK Health Security Agency
- Public Procurement Organisation Number: PBMQ-7576-DVGW
10 South Colonnade
London
E14 4PU
United Kingdom
Email: commercial.preparednessandcountermeasures@ukhsa.gov.uk
Website: https://www.gov.uk/government/organisations/uk-health-security-agency
Region: UKI42 - Tower Hamlets
Organisation type: Public authority - central government